Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1

Interventions

Trastuzumab 3Sugammadex 2Neostigmine 2Cisplatin 2valrubicin 1tucatinib 1pembrolizumab 1niraparib 1enfortumab vedotin 1avelumab 1atezolizumab 1Surveys and Questionnaires 1Sunitinib 1Standard of Care 1Rocuronium 1Pemetrexed 1Paclitaxel 1Nephroureterectomy 1Neoadjuvant Therapy 1Mitomycin 1Lymph Node Excision 1Glycopyrrolate 1Gemcitabine 1GSK-3326595 1Fulvestrant 1Docetaxel 1Cetuximab 1Afatinib 1Administration, Intravesical 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Neoplasms × Nephroureterectomy × Clear all
NCT00751140 2017-05-30

Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
20 enrolled 7 charts
Genitourinary

Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡